STOCK TITAN

Verona Pharma - VRNA STOCK NEWS

Welcome to our dedicated page for Verona Pharma news (Ticker: VRNA), a resource for investors and traders seeking the latest updates and insights on Verona Pharma stock.

Verona Pharma PLC (VRNA) is a clinical-stage biopharmaceutical company advancing innovative therapies for chronic respiratory diseases. This page serves as the definitive source for official news, including updates on clinical trials, regulatory milestones, and strategic partnerships.

Investors and researchers can track developments related to key programs like ensifentrine for COPD treatment, with real-time access to press releases about FDA submissions, trial results, and manufacturing collaborations. Our curated collection ensures you never miss critical updates about respiratory therapy innovations.

Explore verified information on phase III trial progress, regulatory communications, and research partnerships with leading medical institutions. All content is sourced directly from company filings and official statements to maintain accuracy.

Bookmark this page for streamlined access to VRNA's latest advancements in treating COPD, cystic fibrosis, and asthma. Check regularly for developments that shape the future of respiratory care.

Rhea-AI Summary

Verona Pharma plc (Nasdaq: VRNA) has announced it will report its financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024. The company will also host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.

To participate in the call, investors can dial +1-833-816-1396 (US callers) or +1-412-317-0489 (international callers) and ask to join the Verona Pharma call. A live webcast will be available on the Events and Presentations link on the Investors page of the company's website, www.veronapharma.com, with an audio replay available for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
conferences earnings
-
Rhea-AI Summary

Verona Pharma announces six analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for COPD treatment to be presented at CHEST 2024. The presentations include four oral and two poster sessions, highlighting Ohtuvayre's efficacy and safety in various COPD patient subgroups. Key findings show improvements in lung function, symptoms, and quality of life, as well as reduced exacerbation rates, regardless of COPD severity, smoking status, or chronic bronchitis presence.

Ohtuvayre, a first-in-class dual inhibitor of PDE3 and PDE4, combines bronchodilator and anti-inflammatory effects. It's the first novel inhaled mechanism for COPD maintenance treatment in over 20 years. The analyses will also present data on Ohtuvayre's impact on reducing COPD-related healthcare resource utilization over 48 weeks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.03%
Tags
conferences clinical trial
-
Rhea-AI Summary

Ritedose, the largest CDMO in the US specializing in sterile Blow Fill Seal production, has partnered with Verona Pharma (Nasdaq: VRNA) to develop and manufacture Ohtuvayre (ensifentrine), a novel COPD treatment. The FDA approved Ohtuvayre on June 26 for maintenance treatment of COPD in adults, marking the first inhaled product with a new mechanism of action in over 20 years. Ohtuvayre, delivered via standard jet nebulizer, is a first-in-class PDE3 and PDE4 inhibitor that aims to redefine COPD treatment. With COPD affecting over 480 million people globally and 14 million in the US, this partnership between Ritedose and Verona Pharma brings a significant advancement to the respiratory market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.22%
Tags
none
Rhea-AI Summary

Verona Pharma (Nasdaq: VRNA) announces presentations of additional analyses from its Phase 3 ENHANCE studies on Ohtuvayre™ (ensifentrine) for COPD treatment at the ERS International Congress 2024. The presentations include one oral and three posters, highlighting Ohtuvayre's efficacy and safety in various COPD patient subgroups.

Ohtuvayre, a first-in-class dual inhibitor of PDE3 and PDE4, combines bronchodilator and anti-inflammatory effects. Key findings include improvements in lung function, reduced exacerbation rates, and enhanced quality of life across different patient populations. The analyses support Ohtuvayre's potential to benefit a broad range of COPD patients, marking the first novel inhaled mechanism for COPD maintenance treatment in over 20 years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
conferences clinical trial
-
Rhea-AI Summary

Verona Pharma (NASDAQ: VRNA) announced that Ohtuvayre (ensifentrine) is now available in the US for COPD maintenance treatment. Key highlights:

- Over 2,000 HCP visits conducted and 100+ unique HCPs have prescribed Ohtuvayre
- Submitted IND for ensifentrine-glycopyrrolate combination therapy
- Plans to initiate Phase 2 trial for non-cystic fibrosis bronchiectasis in Q3 2024
- Cash position of $404.6 million as of June 30, 2024
- Q2 2024 R&D expenses increased to $19.4 million (Q2 2023: -$2.5 million)
- Q2 2024 SG&A expenses rose to $49.0 million (Q2 2023: $12.4 million)
- Q2 2024 net loss of $70.8 million (Q2 2023: $8.8 million loss)

The company believes its current cash position will fund operations beyond 2026, including Ohtuvayre's US commercial launch.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.6%
Tags
-
Rhea-AI Summary

Verona Pharma (Nasdaq: VRNA) has announced its participation in the 44th Annual Canaccord Growth Conference. The company's senior management will present a company overview on Tuesday, August 13, 2024, at 1:30 p.m. EDT / 6:30 p.m. BST.

Investors and interested parties can access a webcast of the event through the Events and Presentations link on the Investors page of Verona Pharma's website, www.veronapharma.com. This presentation provides an opportunity for the company to showcase its progress and future plans to a wider audience of potential investors and industry professionals.

For those seeking additional information, Verona Pharma has provided contact details for investor relations, US investor enquiries, and international/US media enquiries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.57%
Tags
conferences
Rhea-AI Summary

Verona Pharma plc (Nasdaq: VRNA) has announced it will report its financial results for the second quarter ended June 30, 2024, on Thursday, August 8, 2024. The company will also host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.

To participate in the call, investors can dial +1-833-816-1396 (US callers) or +1-412-317-0489 (international callers) and ask to join the Verona Pharma call. A live webcast will be available on the Events and Presentations link on the Investors page of the company's website, with an audio replay accessible for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.13%
Tags
conferences earnings
-
Rhea-AI Summary

Verona Pharma announced that the FDA has approved Ohtuvayre™ (ensifentrine) for the maintenance treatment of COPD in adults. Ohtuvayre is the first inhaled treatment in over 20 years offering both bronchodilation and non-steroidal anti-inflammatory effects. The drug is unique as a selective dual inhibitor of PDE3 and PDE4 enzymes and is administered via a standard jet nebulizer.

In clinical trials, Ohtuvayre showed significant benefits when used alone or with other treatments and was well-tolerated by patients with moderate to severe COPD. Verona Pharma plans to launch Ohtuvayre in Q3 2024 through specialized pharmacies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.11%
Tags
-
Rhea-AI Summary

Verona Pharma announces its financial results for the first quarter of 2024 and provides a corporate update. The PDUFA Target Action Date for Ensifentrine is set for June 26, 2024, with preparations underway for a potential US launch in the third quarter. The company's strong balance sheet, supported by a recent financing of up to $650 million, is geared towards commercialization and pipeline expansion. Key milestones include launch preparations, COPD disease awareness campaigns, presentations at conferences, and upcoming clinical trials. Financially, cash position remains strong, with R&D expenses and SG&A expenses detailed for the quarter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
Rhea-AI Summary

Verona Pharma secured $650 million in strategic financing from Oaktree and OMERS to support the US commercial launch of ensifentrine and expand clinical activities. The non-dilutive funding extends the cash runway beyond 2026, providing financial flexibility for growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
none
Verona Pharma

Nasdaq:VRNA

VRNA Rankings

VRNA Stock Data

5.01B
45.25M
6.04%
85.2%
10.59%
Biotechnology
Pharmaceutical Preparations
Link
United Kingdom
LONDON